Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAV-240 in Healthy Participants
NCT06933043Phase 1Completed
- Sponsor
- Navigator Medicines
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune diseases and Inflammatory Disorders comparing NAV-240 MAD Cohorts with Placebo MAD Cohorts (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started May 2025; status: completed.
02
Drugs
NAV-240
03
Conditions
autoimmune diseasesInflammatory Disorders
Beyond the preview
Go deeper on NCT06933043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933043.